These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4073837)

  • 1. On the perpetuation of relic genes having an inviable homozygote.
    Koeslag JH; Schach SR
    Ann Hum Genet; 1985 Oct; 49(4):291-302. PubMed ID: 4073837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preconception risk assessment for thalassaemia, sickle cell disease, cystic fibrosis and Tay-Sachs disease.
    Hussein N; Weng SF; Kai J; Kleijnen J; Qureshi N
    Cochrane Database Syst Rev; 2015 Aug; 2015(8):CD010849. PubMed ID: 26264938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population-specific screening by mutation analysis for diseases frequent in Ashkenazi Jews.
    DeMarchi JM; Caskey CT; Richards CS
    Hum Mutat; 1996; 8(2):116-25. PubMed ID: 8844209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carrier screening for cystic fibrosis, Gaucher disease, and Tay-Sachs disease in the Ashkenazi Jewish population: the first 1000 cases at New York University Medical Center, New York, NY.
    Kronn D; Jansen V; Ostrer H
    Arch Intern Med; 1998 Apr; 158(7):777-81. PubMed ID: 9554684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tay-Sachs disease and the role of reproductive compensation in the maintenance of ethnic variations in the incidence of autosomal recessive disease.
    Koeslag JH; Schach SR
    Ann Hum Genet; 1984 Jul; 48(3):275-81. PubMed ID: 6465844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the maintenance of polymorphisms having an inviable homozygote.
    Mayo O
    Ann Hum Genet; 1970 Jan; 33(3):307-17. PubMed ID: 5504229
    [No Abstract]   [Full Text] [Related]  

  • 7. A genetic screening programme for Tay-Sachs disease and cystic fibrosis for Australian Jewish high school students.
    Barlow-Stewart K; Burnett L; Proos A; Howell V; Huq F; Lazarus R; Aizenberg H
    J Med Genet; 2003 Apr; 40(4):e45. PubMed ID: 12676918
    [No Abstract]   [Full Text] [Related]  

  • 8. Prenatal genetic carrier testing using triple disease screening.
    Eng CM; Schechter C; Robinowitz J; Fulop G; Burgert T; Levy B; Zinberg R; Desnick RJ
    JAMA; 1997 Oct; 278(15):1268-72. PubMed ID: 9333269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of a school-based Tay-Sachs and cystic fibrosis genetic carrier screening program.
    Warren E; Anderson R; Proos AL; Burnett LB; Barlow-Stewart K; Hall J
    Genet Med; 2005 Sep; 7(7):484-94. PubMed ID: 16170240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tay-Sachs disease and the persistence of lethal autosomal recessive genes in human populations.
    Koeslag JH; Schach SR; Melzer CW
    S Afr Med J; 1984 Jul; 66(3):87-9. PubMed ID: 6377528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tay Sachs disease in Australia: reduced disease incidence despite stable carrier frequency in Australian Jews.
    Lew RM; Proos AL; Burnett L; Delatycki M; Bankier A; Fietz MJ
    Med J Aust; 2012 Dec; 197(11):652-4. PubMed ID: 23230938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing the potential success of cystic fibrosis carrier screening: lessons learned from Tay-Sachs disease and beta-thalassemia.
    Laberge AM; Watts C; Porter K; Burke W
    Public Health Genomics; 2010; 13(5):310-9. PubMed ID: 19864874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ethical aspects of genetic screening in Israel.
    Sagi M
    Sci Context; 1998; 11(3-4):419-29. PubMed ID: 15168671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carrier screening for Tay-Sachs disease.
    Scriver CR; Clow CL
    Lancet; 1990 Apr; 335(8693):856. PubMed ID: 1969578
    [No Abstract]   [Full Text] [Related]  

  • 15. Population-based carrier screening and prenatal diagnosis.
    Strom CM
    MLO Med Lab Obs; 2004 Aug; 36(8):12-7; quiz 20-1. PubMed ID: 15366363
    [No Abstract]   [Full Text] [Related]  

  • 16. Social mechanisms in the population genetics of Tay-Sachs and other lethal autosomal recessive diseases: a computer simulation model.
    McKusick KB; Schach SR; Koeslag JH
    Am J Med Genet; 1990 Jun; 36(2):178-82. PubMed ID: 2368806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethical Issues with Genetic Testing for Tay-Sachs.
    Clayton T
    J Christ Nurs; 2017; 34(4):246-249. PubMed ID: 28902054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carrier screening for Tay-Sachs disease and cystic fibrosis.
    ten Kate LP; Tijmstra T
    Lancet; 1990 Jun; 335(8704):1527-8. PubMed ID: 1972454
    [No Abstract]   [Full Text] [Related]  

  • 19. Determinants of utilization of Tay-Sachs screening.
    Garber AP; Platt LD; Wang SJ; Jam K; Carlson DE; Rotter JI
    Obstet Gynecol; 1993 Sep; 82(3):460-3. PubMed ID: 8355954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for genetic disorders among Jews: how should the Tay-Sachs screening program be continued?
    Zlotogora J; Leventhal A
    Isr Med Assoc J; 2000 Sep; 2(9):665-7. PubMed ID: 11062764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.